e-ALIGN: Using the patient portal to align medicines with what matters most
Official title: e-ALIGN: A Patient Portal-based Intervention to Align Medications With What Matters Most
Run by Johns Hopkins University · NCT07454824 · Data updated 2026-11-12
This project will see if sending education through the patient portal plus pharmacist-led medication reviews helps people 65 and older with mild cognitive impairment or dementia and their care partners reduce risky brain-active medicines.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 65 Years and up |
| Sex | All |
| Enrollment | 100 (estimated) |
| Sponsor | Johns Hopkins University Academic / other |
| Locations | 1 site (Baltimore, Maryland) |
| Status | Recruiting |
| Started | April 15, 2026 |
| Main results expected | February 6, 2027 |
| Study ends | February 6, 2027 |
| Registry record updated | June 16, 2026 |
| Trial ID | NCT07454824 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are primary care patients aged 65 or older with mild cognitive impairment or dementia, at least one active CNS-PIM, active patient portal use, and a family or other care partner who helps manage medications.
✕Probably not a fit
People living in long-term care facilities or enrolled in hospice, those without patient portal access, or those without CNS-PIMs are unlikely to benefit from this intervention.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
The e-ALIGN pilot identifies older primary care patients (age ≥65) with mild cognitive impairment or dementia who have at least one active central nervous system potentially inappropriate medication and who use the patient portal. Participating patients and their care partners receive educational materials through the portal and a pharmacist conducts a medication review to align prescriptions with patient and care partner goals and target deprescribing of CNS-PIMs. The multicomponent, triadic intervention aims to increase engagement between patients, care partners, and clinicians and to build preliminary data and workflows for a future multisite embedded pragmatic trial. Outcomes will include changes in CNS-PIM use and measures of patient-centered alignment and well-being.
Why it matters
Potential benefit: If successful, the approach could reduce use of risky brain-active medications and improve care that better matches patients' goals and quality of life.
How similar studies have gone: Pharmacist-led deprescribing and medication-review interventions have shown benefit in reducing inappropriate medications, but delivering a triadic portal-based intervention for people with cognitive impairment is novel and largely untested.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients: Age ≥65, with a diagnosis of MCI or dementia based on ICD-10 codes and ≥1 active CNS-PIM, who are active patient portal users. Care partners: * Family or other companions \>21 years who regularly help the patient with managing medications. Exclusion Criteria: * As the trial will be based in primary care, individuals residing in long term care facilities or enrolled in hospice will be excluded.
Where it's running
-
Johns Hopkins Community Physicians
Baltimore, Maryland, United States Recruiting
Study contacts
- Principal investigator: Ariel Green, MD, MPH, PhD — Johns Hopkins University
- Study coordinator: Ariel Green, MD, MPH, PhD
- Email: ariel@jhmi.edu
- Phone: 410-550-6733
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
China HEAD: a large community study on healthy aging and dementia
This study tests whether collecting health, imaging, and biospecimen data from adults in China can help predict who will develop Alzheimer’s disease and related dementias.
-
Aging Brain Health Initiative in Fujian
This observational study will follow about 3,000 older adults in Fujian to see how Alzheimer's-related changes develop and to test new digital tests, biomarkers, and imaging tools for early diagnosis.
-
Photobiomodulation therapy for mild cognitive impairment and mild Alzheimer's disease
This trial tests whether daily transcranial near-infrared light therapy, versus a sham device, can improve cognitive function in adults with mild cognitive impairment or mild Alzheimer's disease.
-
Gut methane and Parkinson's: measuring if a probiotic helps people with Parkinson's, REM sleep behavior disorder, or cognitive concerns
This study tests whether a probiotic containing Limosilactobacillus reuteri can help people with Parkinson's disease, those at high risk for PD, and related cognitive issues by potentially improving gut methane levels and overall symptoms.
-
Primary aldosteronism and thinking/memory problems
This study will see if people aged 40 and older with primary aldosteronism develop memory and thinking problems over 1 to 5 years and which factors influence those changes.
-
Cognitive function, daily independence, and mood in people with dementia or MCI.
We will see how thinking abilities, independence in everyday activities, and mood change over time in people aged 50–86 with dementia or mild cognitive impairment using repeated clinic assessments.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.